Molecular profiling of the "plexinome" in melanoma and pancreatic cancer

Asha Balakrishnan, Junia Y. Penachioni, Simona Lamba, Fonnet E. Bleeker, Carlo Zanon, Monica Rodolfo, Viviana Vallacchi, Aldo Scarpa, Lara Felicioni, Matthias Buck, Antonio Marchetti, Paolo M. Comoglio, Alberto Bardelli, Luca Tamagnone

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Plexins are transmembrane high-affinity receptors for semaphorins, regulating cell guidance, motility, and invasion. Functional evidences implicate semaphorin signals in cancer progression and metastasis. Yet, it is largely unknown whether plexin genes are genetically altered in human tumors. We performed a comprehensive gene copy analysis and mutational profiling of all nine members of the plexin gene family (plexinome), in melanomas and pancreatic ductal adenocarcinomas (PDACs), which are characterized by high metastatic potential and poor prognosis. Gene copy analysis detected amplification of PLXNA4 in melanomas, whereas copy number losses of multiple plexin genes were seen in PDACs. Somatic mutations were detected in PLXNA4, PLXNB3, and PLXNC1; providing the first evidence that these plexins are mutated in human cancer. Functional assays in cellular models revealed that some of these missense mutations result in loss of plexin function. For instance, c.1613G>A, p.R538H mutation in the extracellular domain of PLXNB3 prevented binding of the ligand Sema5A. Moreover, although PLXNA4 signaling can inhibit tumor cell migration, the mutated c.5206C>T, p.H1736Y allele had lost this activity. Our study is the first systematic analysis of the "plexinome" in human tumors, and indicates that multiple mutated plexins may be involved in cancer progression.

Original languageEnglish
Pages (from-to)1167-1174
Number of pages8
JournalHuman Mutation
Volume30
Issue number8
DOIs
Publication statusPublished - Aug 2009

Fingerprint

Pancreatic Neoplasms
Melanoma
Semaphorins
Neoplasms
Genes
Cell Movement
Adenocarcinoma
Mutation
Missense Mutation
Alleles
Neoplasm Metastasis
Ligands
plexin

Keywords

  • Cancer
  • Melanoma
  • Pancreas
  • PLXNA4
  • Semaphorin

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. / Balakrishnan, Asha; Penachioni, Junia Y.; Lamba, Simona; Bleeker, Fonnet E.; Zanon, Carlo; Rodolfo, Monica; Vallacchi, Viviana; Scarpa, Aldo; Felicioni, Lara; Buck, Matthias; Marchetti, Antonio; Comoglio, Paolo M.; Bardelli, Alberto; Tamagnone, Luca.

In: Human Mutation, Vol. 30, No. 8, 08.2009, p. 1167-1174.

Research output: Contribution to journalArticle

Balakrishnan, A, Penachioni, JY, Lamba, S, Bleeker, FE, Zanon, C, Rodolfo, M, Vallacchi, V, Scarpa, A, Felicioni, L, Buck, M, Marchetti, A, Comoglio, PM, Bardelli, A & Tamagnone, L 2009, 'Molecular profiling of the "plexinome" in melanoma and pancreatic cancer', Human Mutation, vol. 30, no. 8, pp. 1167-1174. https://doi.org/10.1002/humu.21017
Balakrishnan, Asha ; Penachioni, Junia Y. ; Lamba, Simona ; Bleeker, Fonnet E. ; Zanon, Carlo ; Rodolfo, Monica ; Vallacchi, Viviana ; Scarpa, Aldo ; Felicioni, Lara ; Buck, Matthias ; Marchetti, Antonio ; Comoglio, Paolo M. ; Bardelli, Alberto ; Tamagnone, Luca. / Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. In: Human Mutation. 2009 ; Vol. 30, No. 8. pp. 1167-1174.
@article{c25c611054584daaaaa7363881ff27d7,
title = "Molecular profiling of the {"}plexinome{"} in melanoma and pancreatic cancer",
abstract = "Plexins are transmembrane high-affinity receptors for semaphorins, regulating cell guidance, motility, and invasion. Functional evidences implicate semaphorin signals in cancer progression and metastasis. Yet, it is largely unknown whether plexin genes are genetically altered in human tumors. We performed a comprehensive gene copy analysis and mutational profiling of all nine members of the plexin gene family (plexinome), in melanomas and pancreatic ductal adenocarcinomas (PDACs), which are characterized by high metastatic potential and poor prognosis. Gene copy analysis detected amplification of PLXNA4 in melanomas, whereas copy number losses of multiple plexin genes were seen in PDACs. Somatic mutations were detected in PLXNA4, PLXNB3, and PLXNC1; providing the first evidence that these plexins are mutated in human cancer. Functional assays in cellular models revealed that some of these missense mutations result in loss of plexin function. For instance, c.1613G>A, p.R538H mutation in the extracellular domain of PLXNB3 prevented binding of the ligand Sema5A. Moreover, although PLXNA4 signaling can inhibit tumor cell migration, the mutated c.5206C>T, p.H1736Y allele had lost this activity. Our study is the first systematic analysis of the {"}plexinome{"} in human tumors, and indicates that multiple mutated plexins may be involved in cancer progression.",
keywords = "Cancer, Melanoma, Pancreas, PLXNA4, Semaphorin",
author = "Asha Balakrishnan and Penachioni, {Junia Y.} and Simona Lamba and Bleeker, {Fonnet E.} and Carlo Zanon and Monica Rodolfo and Viviana Vallacchi and Aldo Scarpa and Lara Felicioni and Matthias Buck and Antonio Marchetti and Comoglio, {Paolo M.} and Alberto Bardelli and Luca Tamagnone",
year = "2009",
month = "8",
doi = "10.1002/humu.21017",
language = "English",
volume = "30",
pages = "1167--1174",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Molecular profiling of the "plexinome" in melanoma and pancreatic cancer

AU - Balakrishnan, Asha

AU - Penachioni, Junia Y.

AU - Lamba, Simona

AU - Bleeker, Fonnet E.

AU - Zanon, Carlo

AU - Rodolfo, Monica

AU - Vallacchi, Viviana

AU - Scarpa, Aldo

AU - Felicioni, Lara

AU - Buck, Matthias

AU - Marchetti, Antonio

AU - Comoglio, Paolo M.

AU - Bardelli, Alberto

AU - Tamagnone, Luca

PY - 2009/8

Y1 - 2009/8

N2 - Plexins are transmembrane high-affinity receptors for semaphorins, regulating cell guidance, motility, and invasion. Functional evidences implicate semaphorin signals in cancer progression and metastasis. Yet, it is largely unknown whether plexin genes are genetically altered in human tumors. We performed a comprehensive gene copy analysis and mutational profiling of all nine members of the plexin gene family (plexinome), in melanomas and pancreatic ductal adenocarcinomas (PDACs), which are characterized by high metastatic potential and poor prognosis. Gene copy analysis detected amplification of PLXNA4 in melanomas, whereas copy number losses of multiple plexin genes were seen in PDACs. Somatic mutations were detected in PLXNA4, PLXNB3, and PLXNC1; providing the first evidence that these plexins are mutated in human cancer. Functional assays in cellular models revealed that some of these missense mutations result in loss of plexin function. For instance, c.1613G>A, p.R538H mutation in the extracellular domain of PLXNB3 prevented binding of the ligand Sema5A. Moreover, although PLXNA4 signaling can inhibit tumor cell migration, the mutated c.5206C>T, p.H1736Y allele had lost this activity. Our study is the first systematic analysis of the "plexinome" in human tumors, and indicates that multiple mutated plexins may be involved in cancer progression.

AB - Plexins are transmembrane high-affinity receptors for semaphorins, regulating cell guidance, motility, and invasion. Functional evidences implicate semaphorin signals in cancer progression and metastasis. Yet, it is largely unknown whether plexin genes are genetically altered in human tumors. We performed a comprehensive gene copy analysis and mutational profiling of all nine members of the plexin gene family (plexinome), in melanomas and pancreatic ductal adenocarcinomas (PDACs), which are characterized by high metastatic potential and poor prognosis. Gene copy analysis detected amplification of PLXNA4 in melanomas, whereas copy number losses of multiple plexin genes were seen in PDACs. Somatic mutations were detected in PLXNA4, PLXNB3, and PLXNC1; providing the first evidence that these plexins are mutated in human cancer. Functional assays in cellular models revealed that some of these missense mutations result in loss of plexin function. For instance, c.1613G>A, p.R538H mutation in the extracellular domain of PLXNB3 prevented binding of the ligand Sema5A. Moreover, although PLXNA4 signaling can inhibit tumor cell migration, the mutated c.5206C>T, p.H1736Y allele had lost this activity. Our study is the first systematic analysis of the "plexinome" in human tumors, and indicates that multiple mutated plexins may be involved in cancer progression.

KW - Cancer

KW - Melanoma

KW - Pancreas

KW - PLXNA4

KW - Semaphorin

UR - http://www.scopus.com/inward/record.url?scp=67749101343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67749101343&partnerID=8YFLogxK

U2 - 10.1002/humu.21017

DO - 10.1002/humu.21017

M3 - Article

C2 - 19462467

AN - SCOPUS:67749101343

VL - 30

SP - 1167

EP - 1174

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 8

ER -